Aurobindo Pharma's Acrotech Launches Adquey in US Dermatology Market
Aurobindo Pharma's subsidiary, Acrotech Biopharma, has launched Adquey ointment in the US, marking its entry into the American dermatology market. Adquey is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and children aged two and above. Originally developed by Otsuka Pharmaceutical, the drug is licensed to Acrotech for US commercialization. The company has established a dedicated dermatology unit to support this launch, targeting a market valued at approximately USD 1.3 billion through July 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 37/100.
Outlets measured: businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 30 Sept, 05:16 pm. Other outlets followed.
- 1